Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference
CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, NuShield®, Novachor™ and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference held April 6-10, 2022 in Phoenix, Arizona.
“As a leading sponsor of this year’s conference, we are excited to share new research on our innovative product portfolio and hear from other thought leaders about advances in wound care,” said Katie Mowry, Assistant Vice President, Research and Development for Organogenesis.
Attendees of this year's event are encouraged to visit the Organogenesis-supported breakfast symposium, "Investigating the Reliability and Transferability of Current RCT Based on Real-World Evidence" held Thursday, April 7, 2022 from 7:30 to 9:00 a.m. MST in room 224 at the Phoenix Convention Center. This panel discussion features Vickie R. Driver, DPM, MS, FACFAS FAAWC, Robert S. Kirsner, MD, PhD, FAAD, William Marston, MD, and Oscar M. Alvarez, PhD, CCT, FAPWCA, and will discuss how randomized controlled trials (RTCs) based on real-world evidence translates to evaluating wound care therapies.
The Organogenesis-sponsored Innovation Theatre lunch, “Practical Utilization of Skin Substitutes for Chronic Wounds Using Prognostic Patient Indicators” will be held Thursday, April 7, 2022 from 12:00 to 1:30 p.m. MST in room 224. This lunch will feature a presentation by Andrew J. Rader, DPM, FAENS, FACFAOM, FAPWCA, FACCWS of Memorial Hospital Wound Care and Nicholas Todd, DPM, FACFAS of Palo Alto Medical Foundation, who will discuss the use of prognostic patient indicators to determine the appropriate course of action for treating chronic wounds.
Attendees are encouraged to visit the Organogenesis exhibit hall booth (#703) to learn more about the latest advanced wound care products and latest studies. Organogenesis tissue regeneration specialists will be available to discuss the full portfolio of Organogenesis solutions that address wounds from head to toe.
The booth will be open during the following hours:
| Thursday, April 7 | 5:15 to 7:45 p.m. MST | |
| Friday, April 8 | 11:30 a.m. to 2:00 p.m. MST | |
| Saturday, April 9 | 11:30 a.m. to 2:00 p.m. MST |
POSTER PRESENTATIONS OF INTEREST INCLUDE:
A Single Center Pilot Study Investigating the Effects of a Native Cross-Linked Extra Cellular Matrix with PHMB Antimicrobial Barrier to Manage Chronic Lower Extremity Wounds Exhibiting Bacterial Contamination as Determined by a Novel Violet-Light Imaging System
Windy Cole, DPM, CWSP1, Janina Krumbeck, PhD
An Alternative Approach to the Management of Wounds Secondary to Diagnosis or Treatment of Skin Cancers
Daniel Kapp, MD, Laura Pfendler, PT, DPT, CWS
Real World Data Analyses of a Bilayered Living Cellular Construct and a Cryopreserved Placental Membrane for Use in Pressure Injuries
Oscar M. Alvarez, PhD, Michael L. Sabolinski, MD
Real World Data Analyses of a Bilayered Living Cellular Construct and a Cryopreserved Cadaveric Skin Allograft for Use in Pressure Injuries
Oscar M. Alvarez, PhD, Michael L. Sabolinski, MD
ABSTRACTS OF INTEREST INCLUDE:
Characterization of a Micronized Native Collagen Wound Matrix And Its Effectiveness In a Swine Full-Thickness Wound Healing Model
Justin T. Avery, Vivek P. Raut, and Katie C. Mowry
Hypothermic Storage of Amnion and Chorion Membranes Retain Native Tissue Characteristics
Katrina A. Harmon Ph.D.1 and Katie C. Mowry Ph.D.1
Robust Durability and Resistance to Degradation of a Native Type I Collagen Matrix with PHMB in vitro
Katrina A. Harmon, Ph.D.1 and Katie C. Mowry Ph.D.1
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," "continue" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Organogenesis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only to the date of this release, and Organogenesis undertakes no obligations to update or revise these statements, except as may be required by law.
Press and Media Inquiries: Lori Freedman lfreedman@organo.com Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com 443-213-0500